CAJ | 학술논문

支气管哮喘(简称哮喘)是由多种细胞和细胞因子参与的慢性呼吸道炎症性疾病,发病机制可能与Th1/Th2细胞因子失衡、CD4+ CD25+T细胞(调节性T细胞,简称Tregs)及Th17/IL-17等异常有关.白介素35是一种新发现的细胞因子,其与Tregs及Th17/IL-17等免疫调节功能密切相关,通过多种途径参与哮喘的发病和调节,有望成为哮喘的治疗新靶点.本文对此相关研究作一综述.
지기관효천(간칭효천)시유다충세포화세포인자삼여적만성호흡도염증성질병,발병궤제가능여Th1/Th2세포인자실형、CD4+ CD25+T세포(조절성T세포,간칭Tregs)급Th17/IL-17등이상유관.백개소35시일충신발현적세포인자,기여Tregs급Th17/IL-17등면역조절공능밀절상관,통과다충도경삼여효천적발병화조절,유망성위효천적치료신파점.본문대차상관연구작일종술.
Bronchial asthma (asthma) is a chronic inflammatory airway disease involved in many cytokines,the mechanism may be related with the imbalance of Th1/Th2 cells or the abnormalities of CD4+CD25+T cells,Th17/IL-17 and so on.Interleukin-35 (IL-35) is a newly discovered cytokine,which is closely related to the immune function of Th17/IL-17 and Tregs.IL-35 may be involved in the pathogenesis of asthma,which is expected to become a new target for the treatment of asthma.This review describes the relative researches on IL-35.